Measuring Treatment Efficacy in CLL @SeattleCCA

Measuring Treatment Efficacy in CLL @SeattleCCA

obr

1 week
4 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA considers whether minimal residual disease (MRD) is a valid endpoint when measuring the efficacy of treatment in chronic lymphocytic lymphoma (CLL).
Up Next Autoplay